Rhinosinusitis with Without Nasal Polyps

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2026-08-26
EMA Authorised: Tezspire (tezepelumab) — AstraZeneca AB
Authorised status for Tezspire (tezepelumab) by AstraZeneca AB for asthma and sinusitis in the EMA, indicating market authorisation.